Moderna
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT03076385
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03014089
© Copyright 2024. All Rights Reserved by MedPath